Profile data is unavailable for this security.
About the company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
- Revenue in USD (TTM)250.43m
- Net income in USD-397.63m
- Incorporated2017
- Employees838.00
- LocationIovance Biotherapeutics Inc825 INDUSTRIAL ROAD, 4TH FLOORSAN CARLOS 94070United StatesUSA
- Phone+1 (650) 260-7120
- Fax+1 (302) 697-4597
- Websitehttps://www.iovance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 939.06m | 162.00 | -- | 5.90 | -- | 6.10 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| GH Research PLC | 0.00 | -42.92m | 939.75m | 50.00 | -- | 3.20 | -- | -- | -0.7313 | -0.7313 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -17.11 | -12.39 | -17.83 | -12.66 | -- | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -9.48 | -- | -- | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 942.06m | 119.00 | 13.49 | 8.35 | 31.40 | 8.10 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| Galecto Inc | 0.00 | -15.84m | 950.38m | 5.00 | -- | 5.98 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 963.06m | -- | 57.21 | 1.42 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -135.27m | 993.37m | 106.00 | -- | 2.45 | -- | -- | -1.73 | -1.73 | 0.00 | 4.18 | 0.00 | -- | -- | 0.00 | -36.90 | -36.70 | -39.10 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 1.00bn | 83.00 | -- | 5.19 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| CareDx Inc | 358.00m | 60.76m | 1.01bn | 644.00 | 23.71 | 3.16 | 13.05 | 2.74 | 0.8055 | 0.8055 | 6.15 | 6.05 | 0.7874 | 4.87 | 6.25 | 555,897.50 | 13.37 | -11.64 | 16.67 | -13.85 | 67.62 | 66.00 | 16.97 | -18.51 | 2.75 | -- | 0.00 | -- | 19.07 | 21.31 | 127.62 | -- | 14.13 | -- |
| Geron Corp | 183.40m | -79.99m | 1.03bn | 229.00 | -- | 4.18 | -- | 5.67 | -0.1202 | -0.1202 | 0.2754 | 0.3896 | 0.3623 | 0.073 | 5.79 | 800,886.40 | -15.80 | -47.39 | -20.34 | -60.65 | 97.70 | -- | -43.61 | -871.15 | 4.87 | -4.25 | 0.4999 | -- | 32,386.92 | 178.45 | 5.19 | -- | 10.49 | -- |
| Iovance Biotherapeutics Inc | 250.43m | -397.63m | 1.03bn | 838.00 | -- | 1.38 | -- | 3.99 | -1.20 | -1.20 | 0.7552 | 1.82 | 0.2642 | 4.22 | 4.09 | 298,836.50 | -41.94 | -50.14 | -48.13 | -56.84 | 23.96 | -- | -158.78 | -1,097.64 | 3.00 | -- | 0.0014 | -- | 13,698.99 | -- | 16.18 | -- | 9.86 | -- |
| Vir Biotechnology Inc | 16.86m | -499.65m | 1.03bn | 408.00 | -- | 1.35 | -- | 63.62 | -3.62 | -3.62 | 0.1223 | 5.73 | 0.0134 | -- | -- | 41,323.53 | -39.69 | -4.58 | -42.97 | -5.34 | 95.94 | -- | -2,963.54 | -13.27 | -- | -- | 0.00 | -- | -13.90 | 55.77 | 15.14 | -- | -3.97 | -- |
| Sana Biotechnology Inc | 0.00 | -234.41m | 1.03bn | 194.00 | -- | 5.09 | -- | -- | -0.9708 | -0.9708 | 0.00 | 0.7447 | 0.00 | -- | -- | 0.00 | -47.13 | -39.42 | -51.39 | -43.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.82 | -- | 5.06 | -- |
| Fortrea Holdings Inc | 2.76bn | -1.03bn | 1.07bn | 14.50k | -- | 1.63 | -- | 0.3438 | -11.38 | -11.24 | 30.33 | 6.30 | 0.8617 | -- | 4.08 | 178,058.10 | -32.08 | -- | -43.77 | -- | 18.61 | -- | -37.23 | -- | -- | -0.5534 | 0.6598 | -- | -5.14 | -- | -756.47 | -- | -- | -- |
| Savara Inc | 0.00 | -115.65m | 1.09bn | 59.00 | -- | 10.68 | -- | -- | -0.535 | -0.535 | 0.00 | 0.5461 | 0.00 | -- | -- | 0.00 | -60.91 | -36.72 | -66.05 | -39.40 | -- | -- | -- | -109,477.80 | -- | -- | 0.2399 | -- | -- | -- | -75.29 | -- | -29.93 | -- |
| Capricor Therapeutics Inc | 11.13m | -81.99m | 1.11bn | 160.00 | -- | 12.90 | -- | 97.22 | -1.80 | -1.80 | 0.2451 | 1.83 | 0.1015 | -- | 47.48 | 69,565.69 | -74.74 | -45.52 | -96.03 | -61.91 | -- | -- | -736.62 | -248.15 | -- | -- | 0.0387 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Iovance Biotherapeutics Inc's reporting currency: US Dollar USD
27.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 24.68m | 6.22% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 21.68m | 5.46% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 13.31m | 3.35% |
| Invenomic Capital Management LPas of 30 Sep 2025 | 10.54m | 2.66% |
| Long Focus Capital Management LLCas of 30 Sep 2025 | 9.12m | 2.30% |
| Palo Alto Investors LPas of 30 Sep 2025 | 7.62m | 1.92% |
| Geode Capital Management LLCas of 30 Sep 2025 | 6.87m | 1.73% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 6.11m | 1.54% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 5.65m | 1.42% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 5.10m | 1.29% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
